Navigation Links
National Drug Development Accelerator Launched
Date:11/20/2008

LENEXA, Kan., Nov. 20 /PRNewswire/ -- KansasBio announced today a bioscience cluster activation initiative to promote the region's human health-care-related bioscience companies that serve the entire drug development continuum. Called the National Drug Development Accelerator (the Accelerator), the alliance comprises companies across Kansas and the Kansas City metropolitan area that represent many of the nation's preferred resources for drug development.

KansasBio says the Accelerator offers a full spectrum of drug development services. From discovery to post market, the alliance of companies offers comprehensive assets to bring pharmaceuticals and biotech drugs to market cost effectively and at a high level of quality.

"Kansas' collection of companies is the answer to the emerging outsourcing trend among pharmaceutical companies," said Angela Kreps, president of KansasBio. "During the last 5 years as pharmaceutical companies have increased outsourcing, and when development budgets are enduring additional scrutiny related to return on investment, our companies are busy bringing the biggest new drugs to market. We will continue to define the value proposition in a tenuous economy."

In the drug development process, where saving one day can mean saving millions of dollars, Kansas service providers have advanced clinical timelines to save pharmaceutical partners days and sometimes weeks. KansasBio cites local companies' responsiveness as one reason that there are 1,950 ongoing clinical trials in the Kansas region -- the fifth highest per capita in the United States. In areas of the state, the number of clinical trials providing access to new treatments has more than doubled during the last 4 years, according to KansasBio.

"The Kansas region has a 30-year history of expertise with the capabilities to go from the chemistry bench to the patient's bedside," said Michael Beckloff, president of Beckloff Associates. "Our cluster represents companies that have helped develop more than 50 of the world's top drugs. We can efficiently move drugs through the development pipeline and help pharmaceutical companies maximize market years and return on investment."

Kansas has a decades-long history of drug development and is home to preferred partners for major pharmaceutical companies. The state has one of the region's greatest geographic concentrations of experienced pharmaceutical development, clinical research and bioscience companies. To learn more about the Accelerator, visit http://www.NDDAccelerator.com.


'/>"/>
SOURCE KansasBio
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
4. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
5. The Government of Quebec and the New Canadian Government Invest in the Creation of an International Biobank
6. International Isotopes Inc. Announces Completion of an Exclusive Distributor Agreement for Sales of New Style Transportation Containers
7. Arrow International Files and Mails Definitive Proxy Materials
8. Niceware International Announces Licensed Vendor Status with ICCBBA, Inc. to Provide ISBT 128-compliant Software
9. DuPont, Genencor International and Tate & Lyle Honored for Groundbreaking Work in Developing Bio-PDO(TM)
10. Viragen International to Reverse Split Its Common Stock
11. Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... TOKYO , June 24, 2016  Regular discussions on ... to take place between the two entities said Poloz. ... in Ottawa , he pointed to the ... and the federal government. ... Poloz said, "Both institutions have common economic goals, why not ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... While the ... such as the Cary 5000 and the 6000i models are higher end machines that ... the height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced ... this eBook by providing practical tips, tools, and strategies for clinical researchers. , ...
Breaking Biology Technology:
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):